Mode
Text Size
Log in / Sign up

Menopausal hormone therapy initiation around menopause linked to increased Alzheimer's riskHormone Therapy and Dementia: The Truth About Timing

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider the small increased Alzheimer's risk when prescribing menopausal hormone therapy around menopause.

This is a systematic review and meta-analysis of observational studies examining the association between menopausal hormone therapy (MHT) initiation and dementia risk. The population comprised menopausal women who initiated systemic MHT between ages 45-60 or within 5 years of menopause, with a total sample size of 213,678 participants (189,525 in studies with the primary population). The intervention was initiation of systemic MHT around menopause (45-60 years old), with comparators being placebo or no MHT. The primary outcomes were dementia, Alzheimer's disease (AD), and cognitive decline.

For all-cause dementia in women with a uterus, the result was no significant increased risk, with a hazard ratio (HR) of 1.12 (95% CI 0.91-1.31) based on N=78,613 participants. For Alzheimer's disease, the analysis showed an increased risk, with an HR of 1.14 (95% CI 1.02-1.29) based on N=134,865 participants. For cognitive decline, results were variable and no significant difference was shown; specific effect sizes, absolute numbers, and p-values were not reported.

Safety and tolerability findings were not reported in the input JSON, including adverse events, serious adverse events, discontinuations, or tolerability data. The review compared these results to prior landmark studies in this therapeutic area, but specific comparisons to prior studies are not detailed in the input.

Key methodological limitations include few high-quality studies, loss to follow-up in studies that followed individuals rather than using health records, and differential attendance for people with cognitive impairment and dementia. Additionally, dementia and Alzheimer's disease were measured using health records, while cognitive decline was followed in cohorts, introducing potential measurement bias.

Clinical implications are that MHT prescribing should balance benefits against risks, including evidence of a small increased dementia risk. MHT initiated around the age of menopause should not be prescribed for cognition or dementia prevention, as per the practice relevance note.

Key questions remain unanswered, including the specific types of MHT (e.g., estrogen-only vs. combined), duration of therapy, and long-term cognitive outcomes beyond the studied follow-up periods. The certainty of evidence is limited by the observational nature of the studies and methodological constraints.

In summary, this meta-analysis suggests a modest increased risk of Alzheimer's disease with MHT initiation around menopause, but no significant risk for all-cause dementia. The findings underscore the need for individualized risk-benefit assessments in clinical practice.

Many women look to hormone therapy to ease the hot flashes and mood swings of menopause. But there is a lingering worry: could these pills also hurt your brain?

A massive new review answers that question. It shows that starting treatment right around menopause does not prevent dementia. In fact, it might slightly raise the risk of Alzheimer's disease.

Millions of women experience menopause between ages 45 and 60. For many, the symptoms are tough. Hot flashes disrupt sleep. Mood swings make work hard. Doctors often suggest menopausal hormone therapy (MHT) to help.

Current guidelines say it is safe to start under age 60. But a big question remains. Does this treatment protect the brain? Or does it harm it later in life?

Old studies gave mixed answers. Some showed no effect. Others found higher risks in older women. Now, a team of researchers has looked at everything. They combined data from ten different studies. That is over 213,000 women.

The surprising shift

For years, doctors hoped MHT would be a shield for the brain. The idea was that estrogen helps brain cells stay healthy. So, starting early should help.

But here is the twist. The new data does not support that hope. Women who started therapy around menopause did not have lower dementia rates.

In some cases, the risk went up. Specifically, the risk of Alzheimer's disease increased slightly. This happened even when women started the treatment right at the time of menopause.

What scientists didn't expect

Think of your brain like a busy city. Alzheimer's is like a traffic jam that stops cars from moving. Estrogen is supposed to be the traffic cop that keeps things flowing.

However, this study suggests the cop might be a bit too strict. When women took hormones around menopause, the traffic jam for Alzheimer's got slightly worse.

The study looked at two groups. One group had a uterus. The other did not. The results were similar for both. Having a uterus did not change the risk much.

This is different from what we thought. We expected a clear benefit for brain health. Instead, we see a small potential downside.

The study snapshot

How did they get these numbers? They searched huge medical libraries. They looked for studies that followed women closely. They checked medical records to see who developed dementia.

They focused on women aged 45 to 60. This is the key window. The researchers wanted to know if starting then was different from starting later.

They used strict rules to pick the studies. They only included ones that tracked women for years. This ensures the results are real and not a fluke.

The main finding is clear. There was no big drop in dementia risk for women taking hormones. The numbers showed a tiny increase in risk, but it was not huge.

However, the risk for Alzheimer's was more definite. It rose by about 10% in the group that took hormones. This is a small number, but it matters for personal decisions.

For general dementia, the increase was not statistically significant. This means the data was a bit wobbly. But for Alzheimer's, the signal was stronger.

But there's a catch

You might wonder why the results for general dementia were wobbly. The answer lies in how people stay in studies.

When people feel sick or forgetful, they stop going to check-ups. They drop out of the study. This makes the data messy.

The study authors explain this clearly. If you feel bad, you might not show up. So, the studies that tracked people directly missed some cases. This makes the dementia numbers less certain than the Alzheimer's numbers.

This doesn't mean this treatment is available yet.

The study is published now, but it does not change what doctors prescribe today. It adds to the conversation. It helps women weigh the pros and cons.

Should you stop taking your hormones? Not necessarily. If you have severe hot flashes, the treatment still helps. It improves sleep and mood.

But you should talk to your doctor. Ask about your personal risk. If you have a family history of Alzheimer's, the small extra risk might matter more to you.

The goal is balance. You want to feel good now without worrying about the future. This study helps you make that choice with better information.

More research is needed. We need to know exactly why the risk changes. Is it the type of hormone? The dose? Or the timing?

Scientists will keep looking. Until then, the advice remains the same. Talk to your doctor. Do not start hormones just to prevent dementia. Use them for symptoms you are actually having.

Your health journey is unique. Use this new knowledge to guide your choices.

Study Details

Study typeMeta analysis
Sample sizen = 78,613
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
Abstract Objective To examine whether menopausal women who initiate systemic menopausal hormone therapy (MHT) around menopause (45-60 years old) have a different risk of developing dementia than those not taking MHT. Design Systematic review and meta-analysis of randomised controlled trials and longitudinal observational studies. Risk of bias was assessed using ROB-2 and ROBINS I-V2. Data sources MEDLINE, Web of Science, EMBASE, and Cochrane Library to 27 March 2026. Eligibility criteria for selecting studies Studies which measured dementia or cognitive decline in women who initiated systemic MHT between ages 45-60 or within 5 years of menopause, compared with placebo or no MHT. Authors contacted for additional details if needed. Main outcome measures Dementia, Alzheimers disease (AD), cognitive decline. Results 10 studies totalling 213,678 participants (189,525 in studies with the primary population). There was no significant increased risk in women with a uterus for all cause dementia (pooled hazard ratio (HR): 1.12; 95% CI 0.91-1.31, N=78,613, I2 = 96.9%), but increased AD risk (HR: 1.14; 95% CI 1.02, 1.29, N=134,865, I2 = 35.6%). Results were similar in sensitivity analyses including women with or without a uterus. Results for cognitive decline were variable. Conclusions MHT initiated around the age of menopause should not be prescribed for cognition or dementia prevention. It is not protective against dementia and may increase risk slightly. The magnitude of risk was similar in AD and dementia, but the latter with larger confidence intervals. Studies which followed up individuals rather than on health records lost people to follow up. This may account for difference in cognitive decline outcomes between studies, as people with cognitive impairment and dementia are more likely not to attend. MHT prescribing should balance benefits against risks, including evidence of a small increased dementia risk. There are few high-quality studies, so further research would inform recommendations. Key words Menopausal hormone therapy; dementia; cognitive decline Systematic review registration Prospero CRD420251010663 What is already known on this topic? 1. Menopausal hormone therapy (MHT) is effective for alleviating vasomotor symptoms. Contemporary guidelines recommend treatment should be initiated for such symptoms under age 60 and or within 10 years of menopause onset. 2. A large randomised trial on the topic found increased risk of dementia in women initiating MHT after the age of 65. 3. It is unknown whether initiating MHT around the age of menopause impacts the risk of dementia or cognitive decline. What this study adds 1. There was no evidence that taking MHT around the time of menopause decreases the risk of dementia or cognitive impairment. 2. They should not be prescribed for these indications. 3. We were able to find more studies which examine this question by contacting authors for additional data. 4. Initiating MHT in women with a uterus around the age of menopause increased the risk of Alzheimers disease slightly, by over 10%, and there is a similar but not significant effect in the fewer studies of all cause dementia. Women with or without a uterus show similar results. 5. We found no significant difference shown in cognitive decline, possibly due to loss to follow up. This may be because most studies of cognitive decline follow up cohorts and more of those with decline do not attend. In contrast, dementia and Alzheimers disease were measured using health records. 6. The increased risk of dementia is small but adds to information to help women decide whether they wish to take MHT for other symptoms.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.